Joshua Lev Sells 12,000 Shares of electroCore (NASDAQ:ECOR) Stock

electroCore, Inc. (NASDAQ:ECOR) CFO Joshua Lev sold 12,000 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $10.22, for a total transaction of $122,640.00. Following the transaction, the chief financial officer owned 84,889 shares of the company’s stock, valued at approximately $867,565.58. The trade was a 12.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

electroCore Price Performance

NASDAQ:ECOR opened at $10.35 on Thursday. electroCore, Inc. has a 12 month low of $4.41 and a 12 month high of $10.95. The firm has a market capitalization of $93.32 million, a PE ratio of -6.23 and a beta of 0.92. The business’s fifty day moving average price is $7.79 and its 200 day moving average price is $7.27.

electroCore (NASDAQ:ECOR) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.09. The company had revenue of $9.45 million during the quarter, compared to the consensus estimate of $9.49 million. electroCore had a negative return on equity of 1,956.38% and a negative net margin of 39.96%. As a group, equities analysts anticipate that electroCore, Inc. will post -1.4 EPS for the current year.

Hedge Funds Weigh In On electroCore

Several institutional investors have recently bought and sold shares of ECOR. NewEdge Advisors LLC raised its position in electroCore by 857.9% during the 1st quarter. NewEdge Advisors LLC now owns 161,955 shares of the company’s stock worth $1,083,000 after buying an additional 145,047 shares during the last quarter. Tejara Capital Ltd purchased a new position in electroCore during the fourth quarter worth about $450,000. International Assets Investment Management LLC lifted its position in electroCore by 15.2% in the fourth quarter. International Assets Investment Management LLC now owns 88,720 shares of the company’s stock valued at $398,000 after purchasing an additional 11,700 shares during the period. DRW Securities LLC acquired a new stake in electroCore in the fourth quarter valued at about $264,000. Finally, Jane Street Group LLC boosted its holdings in electroCore by 114.4% in the 1st quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock valued at $246,000 after purchasing an additional 19,599 shares in the last quarter. 26.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of electroCore in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, electroCore has a consensus rating of “Hold” and a consensus target price of $18.00.

Key Stories Impacting electroCore

Here are the key news stories impacting electroCore this week:

• Positive Sentiment: electroCore’s Truvaga® device was named the Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards. The recognition may improve consumer awareness and support the company’s expansion into the wellness market beyond its prescription-focused nVNS products. Truvaga Named Best Luxury Biohacking & Longevity Brand
• Neutral Sentiment: Reported short interest was zero shares as of August 25, indicating that short sellers are not a significant factor behind current trading activity. Institutional investors own approximately 26.74% of ECOR, with some funds recently adding to their positions.
• Negative Sentiment: CFO Joshua Lev disclosed a series of stock sales totaling 20,000 shares: 12,000 shares at an average $10.22, 5,000 at $9.88 and 3,000 at $9.36. The transactions reduced his direct ownership to 84,889 shares and occurred near the stock’s recent highs, potentially weighing on investor sentiment. electroCore CFO Insider Sales
• Negative Sentiment: electroCore remains unprofitable. In its latest quarter, the company reported a loss of $0.33 per share—better than the expected $0.42 loss—while revenue of $9.45 million was slightly below the $9.49 million consensus estimate. Analysts expect a full-year loss of approximately $1.40 per share, and the overall analyst rating remains “Hold,” alongside a separate “Sell” rating.

About electroCore

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.